Ko 143

Key Product Details

Product Description

Ko 143 is a potent and selective breast cancer resistance protein multidrug transporter (BCRP) inhibitor (EC₉₀ = 26 nM). Displays > 200-fold selectivity over P-gp and MRP-1 transporters. Increases intracellular drug accumulation and reverses BCRP-mediated multidrug resistance. Inhibits ABCB1 and ABCC1 at higher concentrations. Rapidly metabolized in rat plasma.

Product Specifications for Ko 143

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Ko 143

The following data is based on the product molecular weight 469.57.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

5 4 3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.13 mL	10.65 mL	21.30 mL
5 mM	0.43 mL	2.13 mL	4.26 mL
10 mM	0.21 mL	1.06 mL	2.13 mL
50 mM	0.04 mL	0.21 mL	0.43 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 105 publications citing the usage of this product.

• Weidner The inhibitor Ko143 is not specific for ABCG2. J.Pharmacol.Exp.Ther. 2015 PMID: 26148857
• Allen Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etop. resistance and transport, but etop. oral availability is limited primarily by P-glycoprotein. Cancer Res. 2003 PMID: 12649196
• Loevezijn Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines. Bioorg.Med.Chem.Letts. 2001 PMID: 11140726
• Allen Potent and specific inhibition of breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol.Cancer Ther. 2002 PMID: 12477054

Product Documents for Ko 143